Search

Displaying results 2571 - 2580 of 10000 in total
  1. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas … [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

    Categories: Complex Mixtures
  2. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. … It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Nabilone

    go.drugbank.com/drugs/DB00486
    ApprovedInvestigational

    Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS. … CB2 receptors are mainly located in the peripheral nervous system and can be found on lymphoid tissue where they are involved in regulation of immune function [A32676].

  4. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    FDA approved in December 2008. Fospropofol is a Schedule IV controlled substance in the United States under the Controlled Substances Act. … Fospropofol is a water soluble prodrug and is converted to propofol in the liver. Fospropofol is a short acting hypnotic/sedative/anesthetic agent.

  5. Drug

    Carprofen

    go.drugbank.com/drugs/DB00821
    ApprovedVet approvedWithdrawn

    Carprofen was previously used in human medicine for over 10 years (1985-1995). … It is no longer marketed for human usage, after being withdrawn on commercial grounds.

  6. Drug

    Riluzole

    go.drugbank.com/drugs/DB00740
    ApprovedInvestigational

    A glutamate antagonist (receptors, glutamate) used as an anticonvulsant (anticonvulsants) and to prolong the survival of patients with amyotrophic lateral sclerosis.

    Categories: Compounds used in a research, industrial, or household settingProducts: GLENTEK 50MG, RILUTEK 50MG
  7. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system, rolapitant prevents late-phase CINV. … Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults.

  8. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    [L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine]. … [A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006.

    Products: Redtibin (Decitabine) Powder for Injection 50mg/vial
  9. Drug

    Iodixanol

    go.drugbank.com/drugs/DB01249
    Approved

    Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the

    Categories: Compounds used in a research, industrial, or household settingSynonyms: 5,5'-((2-hydroxytrimethylene)bis(acetylimino))bis(N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide)
  10. Drug

    Brensocatib

    go.drugbank.com/drugs/DB15638
    Approved

    [A274348] Brensocatib was approved by the US FDA on August 12, 2025, for use in adults and pediatric patients with NCFB.[L53808,L53813] … [A274348] Brensocatib is a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor that inhibits neutrophil serine proteases, addressing a key driver of this inflammation.

    Synonyms: (S)-N-((S)-1-Cyano-2-(4-(3-methyl-2-oxo-2,3-dihydrobenzo-(d)oxazol-5-yl)phenyl)ethyl)-1,4-oxazepane-2-carboxamide